ESR1 and neoplasm: PostmenopausaiER+ve cohort: ER+ve ≥1% of tumor cells positive. Triple negative cohort: AR+ tumors− any nuclear AR staining, ER−ve <1% of cells, PR−ve <1% of tumor cells, HER2 with 0, 1+ or 2+ intensity on IHC and no evidence of amplification of the HER2 gene